2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172904
    Antidiabetic agent 15 98%
    Antidiabetic agent 15 (compound 1B15) is a AT1R and NEP dual inhibitor. Antidiabetic agent 15 reduces the oxidative stress and restores the mitochondrial membrane potential.
    Antidiabetic agent 15
  • HY-172924
    NLX-266 2170564-20-0 98%
    NLX-266 is an orally active ERK1/2-biased 5-HT1A receptor agonist. NLX-266 can be used in the study of Parkinson's disease.
    NLX-266
  • HY-172952
    LRRK2-IN-17 2101821-86-5 98%
    LRRK2-IN-17 (Compound 6) is an orally active LRRK2 inhibitor (IC50: 3.5 and 3.3 nM for WT and G2019S, respectively). LRRK2-IN-17 inhibits RET kinase (IC50: 59 nM). LRRK2-IN-17 can be used in cancer and Parkinson's disease (PD) research.
    LRRK2-IN-17
  • HY-172972
    Mitochondrial-IN-1 2001090-87-3 98%
    Mitochondrial-IN (C458) is a potent mitochondrial complex I inhibitor. Mitochondrial-IN demonstrates high protection against Aβ toxicity, favorable pharmacokinetics, and minimal off-target effects.
    Mitochondrial-IN-1
  • HY-172977
    FGA139 98%
    FGA139 is a cysteine proteases inhibitor with IC50 values of 4.98/3.14 μM for cathepsin B/L. FGA139 reduces LPS-induced NO production in RAW264.7 cells and tumor necrosis factor (TNFα) levels in microglia, and has anti-oxidative stress and anti-inflammatory activities. FGA139 promotes the secretion of neuroprotective metabolites purine and linoleic acid by LPS-stimulated microglia. FGA139 can be used in neuroinflammatory diseases research.
    FGA139
  • HY-172978
    5-HT2A receptor agonist-8 2855122-44-8 98%
    5-HT2A receptor agonist-8 (compound 8) is a potent 5-HT2A receptor agonist with an EC50 of 0.6784 nM. 5-HT2A receptor agonist-8 can be used in the study of depressive disorders and bipolar disorders.
    5-HT2A receptor agonist-8
  • HY-172979
    DH-1-106 98%
    DH-1-106 is a MOR partial agonist. DH-1-106 can be used in the study of analgesia.
    DH-1-106
  • HY-172980
    5-HT2A receptor agonist-9 3035280-33-9 98%
    5-HT2A receptor agonist-9 (Compound 9) is a β-arrestin-biased 5-HT2A receptor agonist. 5-HT2A receptor agonist-9 can be used in the research of neurological diseases such as antidepressant and psychedelic.
    5-HT2A receptor agonist-9
  • HY-172981
    CTW0404 2913202-87-4 98%
    CTW0404 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0404 is promising for research of neuropsychiatric disorders.
    CTW0404
  • HY-172982
    CTW0419 98%
    CTW0419 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0419 is promising for research of neuropsychiatric disorders.
    CTW0419
  • HY-172985
    CIT-ALD 211800-31-6
    CIT-ALD is an aldehyde intermediate in the metabolism of Citalopram (HY-121203). CIT-ALD is promising for research of neurological diseases.
    CIT-ALD
  • HY-172995
    RS130-180
    RS130-180 is a selective β-arrestin-biased agonist targeting the serotonin 2A receptor (5-HT2aR). RS130-180 is promising for research of neuropsychiatric disorders such as depression.
    RS130-180
  • HY-172998
    Nav1.8-IN-18 3003828-55-2 98%
    Nav1.8-IN-19 (Compound 70) is a Nav1.8 inhibitor.
    Nav1.8-IN-18
  • HY-172999
    Nav1.8-IN-19 3003829-05-5 98%
    Nav1.8-IN-19 (Compound 122) is a Nav1.8 inhibitor with an IC50 of 0.44 nM in HEK cells. Nav1.8-IN-19 can be used for the study of pain.
    Nav1.8-IN-19
  • HY-173016
    HINT1-IN-1 98%
    HINT1-IN-1 (Compound 8) is the inhibitor for histidine triad nucleotide-binding protein 1 (HINT1) with a Ki of 1.14 μM. HINT1-IN-1 affects the cross-regulation between μ-opioid receptor (MOR) and NMDA receptor (NMDAR). HINT1-IN-1 enhances the analgesic effect of morphine without causing opioid tolerance and has independent analgesic effects in mouse model.
    HINT1-IN-1
  • HY-173024
    TRPC4/5-IN-3 3053390-98-7 99.65%
    TRPC4/5-IN-3 (Compound 32) is the orally active inhibitor for transient receptor potential canonical channel 4/5 (TRPC4/5) with IC50 of 3.6 nM and 5.5 nM. TRPC4/5-IN-3 inhibits hERG channel with IC50 of 6.5 µM. TRPC4/5-IN-3 exhibits good metabolic stability in human/rat/mouse liver microsomes. TRPC4/5-IN-3 exhibits antidepressant and anxiolytic activity in mouse models, exhibits good pharmacokinetic characteristics in mouse with an oral bioavailability of 87%.
    TRPC4/5-IN-3
  • HY-173030
    Opioid receptor agonist 1 98%
    Opioid receptor agonist 1 (Compound 2638-28) is the orally active agonist for opioid receptor that exhibits good affinity to MOR, DOR and KOR with Ki of 5, 24 and 212 nM, respectively. Opioid receptor agonist 1 exhibits analgesic activity in mouse warm water tail flick models and acetic acid writhing models.
    Opioid receptor agonist 1
  • HY-173031
    KTX-005 162182-77-6 98%
    KTX-005 is the agonist for mAChR that regulates the signaling pathway of the neurotransmitter acetylcholine, and can be used for research of schizophrenia.
    KTX-005
  • HY-173032
    VU6033685 98%
    VU6033685 is the orally active positive allosteric modulator (PAM) for mGlu1 that positively modulates human mGlu1 and human mGlu5 with EC50 of 39 nM and 3960 nM. VU6033685 also inhibits CYP1A2, CYP2C9 and CYP2D6 with IC50 of 26, 22.3 and 23.8 μM, respectively. VU6033685 reverses amphetamine-induced rats hyperlocomotion, protects rats from MK-801 (HY-15084B)-induced cognitive impairment. VU6033685 exhibits good pharmacokinetics characteristics in rats with an oral bioavailability of 42.8%.
    VU6033685
  • HY-173044
    5-HT1AR/5-HT6R ligand-1 98%
    5-HT1AR/5-HT6R ligand-1 (Compound PP13) is the ligand for 5-HT receptor that exhibits good affinity to 5-HT1AR, 5-HT6R and 5-HT7R (Ki of 19, 69 and 198 nM, respectively), thereby inhibiting the cAMP production in HEK293 cell with EC50 of 1535, 488 and 53 nM, respectively. 5-HT1AR/5-HT6R ligand-1 exhibits anti-proliferative activity against a variety of cancer cells (IC50 for 1321N1, U87MG, MCF7, and AsPC-1 is 9.6, 13.6, 19.3 and 14.6 μM, respectively). 5-HT1AR/5-HT6R ligand-1 also exhibits antagonist activity for dopamine receptor D2R with Ki of 1903 nM.
    5-HT1AR/5-HT6R ligand-1
Cat. No. Product Name / Synonyms Application Reactivity